T. K. Tan

This paper develops a bivalent binding model to analyze how molecular reach affects SARS-CoV-2 neutralization potency across antibodies.

A vaccine candidate with polyprotein antigens displayed on nanocages induces neutralizing antibodies to multiple SARS-like coronaviruses.

This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.

This study shows BMAL1 regulates ACE2 expression and SARS-CoV-2 entry in lung epithelial cells, with SR9009 reducing viral replication through circadian mechanisms.

This paper identifies CR3022 as a monoclonal antibody that neutralizes SARS-CoV-2 by destroying its prefusion Spike conformation, suggesting therapeutic potential.

This study develops a vaccine candidate using SpyCatcher technology to display the SARS-CoV-2 RBD, showing strong neutralizing antibody responses in mice and pigs.

The paper develops a biparatopic antibody-ACE2 fusion (89C8-ACE2) that effectively blocks SARS-CoV-2 infection in vitro and neutralizes authentic virus at low nanomolar concentrations.

This paper identifies an antibody, EY6A, from a convalescent patient that neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 by binding a conserved epitope on the Spike protein.

This study shows that incorporating cGAMP into virus-like particles (VLPs) enhances their immunogenicity, leading to stronger T cell responses and antibody titres against HIV and influenza viruses.

This study identifies broadly reactive human monoclonal antibodies against N1 neuraminidase from vaccination and H7N9 infection, showing cross-inhibition of diverse N1 NAs and protective efficacy in mice.